CRBSI - Catheter Related Bloodstream Infection
0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Becton DickinsonFRANKLIN LAKES, NJ
2 programsBD PosiFlush SafeScrubN/A
BD PosiFlush™ SafeScrubN/A1 trial
Active Trials
UNION therapeuticsDenmark - Hellerup
1 programevidence-based intervention Plan for the Prevention of CRBSI in ICU patientsN/A1 trial
Active Trials
Autonomous TherapeuticsMD - Rockville
1 programevidence-based intervention Plan for the Prevention of CRBSI in ICU patientsN/A
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Becton DickinsonBD PosiFlush™ SafeScrub
UNION therapeuticsevidence-based intervention Plan for the Prevention of CRBSI in ICU patients
Clinical Trials (2)
Total enrollment: 8,272 patients across 2 trials
Investigational Study With the BD PosiFlush™ SafeScrub on NADs
Start: Oct 2024Est. completion: Apr 2026222 patients
N/ACompleted
NCT06085690UNION therapeuticsevidence-based intervention Plan for the Prevention of CRBSI in ICU patients
Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science
Start: Sep 2023Est. completion: Dec 20258,050 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 8,272 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.